Dr. Michael Krohn
is our expert and business contact in the field of CRISPR
With our own CRISPR-Cas genome scissors, we meet customer project goals faster and cheaper
Chronological development and type of targeted genome modifications: Targeted genome modifications can be achieved using rare cleaving nucleases, such as zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), meganucleases (mns, also termed homing endonucleases); MegaTals as fusions of meganucleases and Talens; and clustered, regularly interspaced, short palindromic repeat (CRISPR) RNA-guided nucleases.
Our novel CRISPR-associated nuclease has been validated both internally and externally with partners and has demonstrated DNA targeting activity in selected bacteria, fungi and yeasts. Accordingly, the technology is ready for use in developments based on these organisms. Activity in plants has also been demonstrated, but validation is pending. Genome editing tests for other application areas such as mammalian cell lines are currently ongoing (as of July 2021).
We are already successfully using BEC not only in our own projects, but also in customer projects.